A retrospective study to assess blood biomarkers associated with survival outcome in non-small cell lung cancer patients treated with ICIs monotherapy
Latest Information Update: 23 Jun 2020
At a glance
- Drugs Durvalumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
Most Recent Events
- 23 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology